Skip to main navigation Skip to search Skip to main content

Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis

  • Jun Ho Yi
  • , Seok Jin Kim
  • , Dok Hyun Yoon
  • , Cheolwon Suh
  • , Myung Hee Chang
  • , Deok Hwan Yang
  • , Jae Cheol Jo
  • , Shin Young Hyun
  • , Hyeon Seok Eom
  • , Jeong Ok Lee
  • , Ji Hyun Kwon
  • , Sang Hoon Han
  • , Seung Shin Lee
  • , Jae Yong Kwak
  • , Se Hyung Kim
  • , Dae Sik Kim
  • , Ji Hyun Lee
  • , Sung Yong Oh
  • , Hun Mo Ryoo
  • , Hyo Jung Kim
  • Won Seog Kim
  • Chung-Ang University
  • Sungkyunkwan University
  • University of Ulsan
  • National Health Insurance Corporation Ilsan Hospital
  • Chonnam National University
  • Yonsei University Wonju College of Medicine
  • National Cancer Center Korea
  • Seoul National University
  • Chungbuk National University
  • Jeju National University
  • Wonkwang University
  • Jeonbuk National University
  • Soonchunhyang University
  • Korea University
  • Dong-A University
  • Catholic University of Daegu
  • Hallym University

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)275-278
Number of pages4
JournalCancer Communications
Volume41
Issue number3
DOIs
StatePublished - Mar 2021
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this